ASCO GU: Many kidney cancer patients left out of clinical trial discussions, survey reveals
Older kidney cancer patients also lack understanding of their remission and survival diagnosis.
By
Homepage
Latest in
Homepage
Pipeline Moves: CuraSen’s Parkinson’s disease and MCI asset’s advancement prospects change with Phase I updates
Rivus and Madrigal’s respective nonalcoholic steatohepatitis assets are also reviewed by Clinical Trials Arena.
By
Pipeline Moves: Roche Phase I suspension plummets further study chances in blood cancers
Celularity in glioblastoma multiforme and Sino Biopharm in gastric cancer are also reviewed by Clinical Trials Arena.
By
Are you ready? EU’s Clinical Trials Regulation and portal goes live 31 January
The EU’s Clinical Trials Regulation and information system aims to streamline applications and bolster transparency – but initial rollout could…
By
Pipeline Moves: Pfizer completes Phase I trial, boosts NASH program
iOnctura’s and Blade’s respective assets in idiopathic pulmonary fibrosis are also reviewed by Clinical Trials Arena.
By
Revealed: pharma leaders in precision, personalised medicine
GlobalData’s Thematic Research ecosystem ranks companies on a scale of 1 to 5 based on their likelihood to tackle issues…
By
Trial Activity Snapshot: Did Australia’s “zero-Covid” plan protect clinical trial activity?
In an exclusive, Clinical Trials Arena dives into Australia’s trial activity data to find out how the pandemic impacted the…
By
Biosimilars: top 10 pharma companies leading the way
The analysis is influenced by new biosimilars jobs, deals, patents, and mentions in company reports since January 2021.
By